ADVL1322 (VEG116731/PZP034X2203), A Phase II Study of Pazopanib (GW786034, NSC#737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors

Protocol: 
AAAP3554
Phase: 
II

ADVL1322 (VEG116731/PZP034X2203), A Phase II Study of Pazopanib (GW786034, NSC#737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors

The purpose of this study is to find out what effects, good or bad, pazopanib
has on children and adolescents with relapsed or refractory solid tumors.
Pazopanib is a drug that blocks blood vessel growth via blockade of a growth
factor (known as VEGF). It has been shown in several studies to be an
effective cancer therapy. Patients will receive Pazopanib as an oral tablet
or suspension once a day and will be monitored with clinical and laboratory
tests for side effects.

Are you Eligible? (Inclusion Criteria)

-At least 1 year and up to 18 years of age at the time of study entry.
-Patients must have one of the following types of cancer: a)
Rhabdomyosarcoma, b) Non-rhabdomyosarcomatous Soft Tissue Sarcoma (including
desmoplastic small round cell tumor), c) Ewing Sarcoma / Peripheral Primitive
Neuroectodermal Tumor (PNET), d) Osteosarcoma, e) Neuroblastoma (Measurable),
f) Neuroblastoma (Evaluable), g) Hepatoblastoma.
-Relapsed or refractory disease
-Patients must also meet all other eligibility criteria as outlined in the
study

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States